Semaglutide is a recombinant DNA produced polypeptide analog of human glucagon-like peptide-1 (GLP-1) which is used in combination with diet and exercise in the therapy of type 2 diabetes, either alone or in combination with other antidiabetic agents.
CAT No: R1847
CAS No:910463-68-2
Synonyms/Alias:Semaglutide;Rybelsus;Ozempic;910463-68-2;Wegovy;NN9535;UNII-53AXN4NNHX;NN 9535;NNC 0113-0217;53AXN4NNHX;NN-9535;Rybelsus (oral semaglutide);Ozempic (injectable semaglutide);CHEBI:167574;NNC-0113-0217;Semaglutide [USAN:INN];semaglutida;semaglutidum;Oral Semaglutide;Semaglutide free base;Semaglutide(sodium salt)?;GTPL9724;A10BJ06;DTXSID101027903;EX-A2424;AC-32580;FS171058;NNC0480 0389;NN1535 ICOSEMA COMPONENT SEMAGLUTIDE;NN1535 LAISEMA COMPONENT SEMAGLUTIDE;SEMAGLUTIDE COMPONENT OF NN1535 ICOSEMA;Rybelsus;Ozempic;NN9535;OG217SC;NNC 0113-0217;
3. Autoinhibition and phosphorylation-induced activation of phospholipase C-γ isozymes
5. Peptides as Active Ingredients: A Challenge for Cosmeceutical Industry
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.